HWHarry J. Witchel

Harry J. Witchel

*This is an algorithmically generated author record based on publicly available information.

Harry J. Witchel has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Inhibition of the HERG potassium channel by the tricyclic antidepressant doxepin

    by R.S. Duncan, M.J. McPate, J.M. Ridley, Z. Gao, A.F. James, D.J. Leishman, J.L. Leaney, H.J. Witchel, J.C. Hancox


  • The hERG potassium channel as a therapeutic target

    by Harry J Witchel

    The hERG (human ether-à-go-go-related gene) potassium channel has elicited intense scientific interest due to its counter-intuitive kinetics and its association with arrhythmia and sudden death. hERG blockade is involved in both antiarrhythmic pharmacotherapy and the pathogenesis of familial and acquired long QT syndrome (LQTS). Short QT syndrome (SQTS), muscular atrophy and many forms of cancer have also been associated with hERG as a target. Molecular models of both the channel and its blocker pharmacophores exist, revealing methods to design hERG liability out of potential drug molecules. Future developments will synthesise preclinical data on hERG with other criteria to determine net arrhythmogenic risk. Also, the molecular actions of hERG and its genetics will be elucidated in detail to allow clinical risk reduction.


  • The Low-Potency, Voltage-Dependent HERG Blocker Propafenone—Molecular Determinants and Drug Trapping

    by Harry J. Witchel, Christopher E Dempsey, Richard B. Sessions, Matthew Perry, James T. Milnes, Jules C. Hancox, John S. Mitcheson

    The molecular determinants of high-affinity human ether-a-go-go-related gene (HERG) potassium channel blockade by methanesulfonanilides include two aromatic residues (Phe656 and Tyr652) on the inner helices (S6) and residues on the pore helices that face into the inner cavity, but determinants for lower-affinity HERG blockers may be different. In this study, alanine-substituted HERG channel mutants of inner cavity residues were expressed in Xenopus laevis oocytes and were used to characterize the HERG channel binding site of the antiarrhythmic propafenone. Propafenone's blockade of HERG was strongly dependent on residue Phe656 but was insensitive or weakly sensitive to mutation of Tyr652, Thr623, Ser624, Val625, Gly648, or Val659 and did not require functional inactivation. Homology models of HERG based on KcsA and MthK crystal structures, representing the closed and open forms of the channel, respectively, suggest propafenone is trapped in the inner cavity and is unable to interact exclusively with Phe656 in the closed state (whereas exclusive interactions between propafenone and Phe656 are found in the open-channel model). These findings are supported by very slow recovery of wild-type HERG channels from block at -120 mV, but extremely rapid recovery of D540K channels that reopen at this potential. The experiments and modeling suggest that the open-state propafenone binding-site may be formed by the Phe656 residues alone. The binding site for propafenone (which may involve π-stacking interactions with two or more Phe656 side-chains) is either perturbed or becomes less accessible because of closed-channel gating. This provides further evidence for the existence of gating-induced changes in the spatial location of Phe656 side chains.


  • Moderately elevated plasma homocysteine impairs functional endothelial recovery following denudation of mouse carotid arteries*1

    by Alastair L Miller, Harry J Witchel, Jules C Hancox, Christopher L Jackson, Jamie Y Jeremy

  • Blockade of HERG potassium currents by fluvoxamine: incomplete attenuation by S6 mutations at F656 or Y652

    by James T Milnes, Olivia Crociani, Annarosa Arcangeli, Jules C Hancox, Harry J Witchel

    Pharmacological blockade of the Human ether‐a‐go‐go related gene (HERG) potassium channel is commonly linked with acquired long QT syndrome and associated proarrhythmia. The objectives of this study were (i) to identify and characterise any inhibitory action on HERG of the selective‐serotonin re‐uptake inhibitor fluvoxamine, (ii) to then determine whether fluvoxamine shared the consensus molecular determinants of HERG blockade of those drugs so far tested. Heterologous HERG potassium current (IHERG) was measured at 37°C, using the whole‐cell patch‐clamp technique, from a mammalian cell line (Human embryonic kidney 293) expressing HERG channels. IHERG tails, following repolarisation from +20 to −40 mV, were blocked by fluvoxamine with an IC50 of 3.8 μM. Blockade of wild‐type HERG was of extremely rapid onset (within 10 ms) and showed voltage dependence, with fluvoxamine also inducing a leftward shift in voltage‐dependent activation of IHERG. Characteristics of block were consistent with a component of closed channel (or extremely rapidly developing open channel) blockade and dependence on open and inactivated channel states. The attenuated‐inactivation mutation S631A partially reduced the blocking effect of fluvoxamine. The S6 mutations, Y652A and F656A, and the pore helix mutant S631A only partially attenuated blockade by fluvoxamine at concentrations causing profound blockade of wild‐type HERG. All HERG‐blocking pharmaceuticals studied to date have been shown to block F656 mutant channels with over 100‐fold reduced potency compared to their blockade of the wild‐type channel. Fluvoxamine is therefore quite distinct in this regard from previously studied agents. British Journal of Pharmacology (2003) 139, 887–898. doi:10.1038/sj.bjp.0705335


  • Psychotropic Drugs, Cardiac Arrhythmia, and Sudden Death

    by Harry J. Witchel, Jules C. Hancox, David J. Nutt

    A variety of drugs targeted towards the central nervous system are associated with cardiac side effects, some of which are linked with reports of arrhythmia and sudden death. Some psychotropic drugs, particularly tricyclic antidepressants (TCAs) and antipsychotic agents, are correlated with iatrogenic prolongation of the QT interval of the electrocardiogram (ECG). In turn, this is associated with the arrhythmia torsades de pointes (TdP). This review discusses the association between psychotropic agents, arrhythmia and sudden death and, focusing on TCAs and antipsychotics, considers their range of cellular actions on the heart; potentially pro-arrhythmic interactions between psychotropic and other medications are also considered. At the cellular level TCAs, such as imipramine and amitriptyline, and antipsychotics, such as thioridazine, are associated with inhibition of potassium channels encoded by HERG. In many cases this cellular action correlates with ECG changes and a risk of TdP. However, not all psychotropic agents that inhibit HERG at the cellular level are associated equally with QT prolongation in patients, and the potential for QT prolongation is not always equally correlated with TdP. Differences in risk between classes of psychotropic drugs, and between individual drugs within a class, may result from additional cellular effects of particular agents, which may influence the consequent effects of inhibition of repolarizing potassium current.


  • Familial And Acquired Long QT Syndrome And The Cardiac Rapid Delayed Rectifier Potassium Current

    by Harry J Witchel, Jules C Hancox

    SUMMARY: 1. Long QT syndrome (LQTS) is a cardiac disorder characterized by syncope, seizures and sudden death; it can be congenital, idiopathic, or iatrogenic.2. Long QT syndrome is so‐named because of the connection observed between the distinctive polymorphic ventricular tachycardia torsade de pointes and prolongation of the QT interval of the electrocardiogram, reflecting abnormally slowed ventricular action potential (AP) repolarization. Acquired LQTS has many similar clinical features to congenital LQTS, but typically affects older individuals and is often associated with specific pharmacological agents.3. A growing number of drugs associated with QT prolongation and its concomitant risks of arrhythmia and sudden death have been shown to block the ‘rapid’ cardiac delayed rectifier potassium current (IKr) or cloned channels encoded by the human ether‐a‐go‐go‐related gene (HERG; the gene believed to encode native IKr). Because IKr plays an important role in ventricular AP repolarization, its inhibition would be expected to result in prolongation of both the AP and QT interval of the electrocardiogram.4. The drugs that produce acquired LQTS are structurally heterogeneous, including anti‐arrhythmics, such as quinidine, non‐sedating antihistamines, such as terfenadine, and psychiatric drugs, such as haloperidol. In addition to heterogeneity in their structure, the electrophysiological characteristics of HERG/IKr inhibition differ between agents.5. Here, clinical observations are associated with cellular data to correlate acquired LQTS with the IKr/HERG potassium (K+) channel. One strategy for developing improved compounds in those drug classes that are currently associated with LQTS could be to design drug structures that preserve clinical efficacy but are modified to avoid pharmacological interactions with IKr. Until such time, awareness of the QT‐prolongation risk of particular agents is important for the clinician.


  • Inhibition of the current of heterologously expressed HERG potassium channels by imipramine and amitriptyline

    by Anja G Teschemacher, Elizabeth P Seward, Jules C Hancox, Harry J Witchel

    Tricyclic antidepressants (TCAs) are associated with cardiovascular side effects including prolongation of the QT interval of the ECG. In this report we studied the effects of two TCAs (imipramine and amitriptyline) on ionic current mediated by cloned HERG potassium channels. Voltage clamp measurements of HERG currents were made from CHO cells transiently transfected with HERG cDNA. HERG‐encoded potassium channels were inhibited in a reversible manner by both imipramine and amitriptyline. HERG tail currents (IHERG) following test pulses to +20 mV were inhibited by imipramine with an IC50 of 3.4±0.4 μM (mean±s.e.mean) and a Hill coefficient of 1.17±0.03 (n=5). 3 μM amitriptyline inhibited IHERG by 34±6% (n=3). The inhibition showed only weak voltage dependence. Using an ‘envelope of tails’ comprised of pulses to +20 mV of varying durations, the τ of activation was found to be 155±30 ms for control and 132±26 ms for 3 μM imipramine (n=5). Once maximal channel activation was achieved after 320 ms (as demonstrated by maximal tail currents), further prolongation of depolarization did not increase imipramine‐mediated HERG channel inhibition. Taking current measurements every second during a 10 s depolarizing pulse from −80 mV to 0 mV, block was observed during the first pulse in the presence of imipramine and the level of IHERG block was similar throughout the pulse (n=5). A three pulse protocol (two depolarizing pulses to +20 mV separated by 20 ms at −80 mV) revealed that imipramine did not significantly alter the kinetics of IHERG inactivation. The τ of inactivation was 8±2 ms and 5.6±0.4 ms (n=5) in the absence and presence of 3 μM imipramine, respectively, and currents inactivated to a similar extent. Our data are consistent with TCAs causing components of block of the HERG channel in both the closed and open states. Any component of open channel block occurs rapidly upon depolarization. Inhibition of IHERG by the prototype TCAs imipramine and amitriptyline may suggest a mechanism for QT prolongation associated with risks of arrhythmia and sudden death that accompany high concentrations of TCAs following overdose. British Journal of Pharmacology (1999) 128, 479–485; doi:10.1038/sj.bjp.0702800


  • Open Access

    Milligram Quantity Preparation of RNA from a Marine Invertebrate with a High Fluid Content

    by Harry J. Witchel, Norman J. Maitland, Robert W. Meech